Study of Inflammation and Mortality After Acute Coronary Syndrome in Adults Aged 18 to 85 Treated with PCI

What this Trial Is About

Researchers are evaluating the role of the neutrophil-to-lymphocyte ratio NLR as a predictor of mortality in patients who have had an episode of Acute Coronary Syndrome ACS. This observational study focuses on patients admitted with a confirmed diagnosis of ACS, including STEMI and Non-STEMI, who are treated with percutaneous coronary intervention PCI. The study aims to determine if NLR, a simple and cost-effective blood test marker, can help predict death and major heart events within six months after ACS, improving early risk assessment and patient outcomes. Participants will have their NLR measured from blood samples taken at hospital admission, then again at 24 and 48 hours after PCI. The study will collect detailed clinical data including patient information, angiography results, and various blood markers like C-reactive protein and troponin levels. Follow-up will occur through telephone interviews up to six months after discharge, using standardized questionnaires to assess patient health and symptoms. During the study, patients health status will be evaluated at 24 hours, 48 hours, and six months after symptom onset. Researchers will monitor mortality rates, major adverse cardiac events, and associations of NLR with other clinical factors. This comprehensive approach includes gathering clinical records, laboratory results, and patient-reported outcomes to better understand NLRs value in predicting post-ACS risks and potentially guiding future care strategies.

TIRANA-ACS: A Prospective Registry Study for the Targeted Investigation of Residual Inflammation After Non-ST/ ST Elevation Acute Coronary Syndrome